Co-director, UCLA Program in Preventive Cardiology
Cardiology
Dr. Karol E. Watson, MD
|
|
Give Review
Karol Watson practices Cardiology. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He has 4 awards "CMS Meaningful Use Stage 1 Certification", "Whos Who in Medicine and Healthcare", "Fellow (FACC)" and "Super Doctor". Karol E. Watson, MD is also a published physician. He has 96 paper published. The most recent paper is: Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Karol Watson accepts Medicare payments and is listed with Medicare.gov.
Publications
- Slippery Slope of Triglycerides: They Are Associated With Risk, But in the Statin Era, Does Targeting Them Confer Benefit?
- Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.
- Association of subclinical atherosclerosis using carotid intima-media thickness, carotid plaque, and Coronary calcium score with left ventricular dyssynchrony: The mul...
- Harnessing the Heart of Big Data.
- Usefulness of N-terminal Pro-brain Natriuretic Peptide and Myocardial Perfusion in Asymptomatic Adults (from the Multi-Ethnic Study of Atherosclerosis).
- Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis.
- Practical Implementation of the 2013 AHA/ACC Blood Cholesterol Guidelines.
- Association of menopause age and N-terminal pro brain natriuretic peptide: the Multi-Ethnic Study of Atherosclerosis.
- Is there sufficient enhancement of the reduction in CVD rates after a decade of statin therapy to justify continuation?
- Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes.
- Abdominal Aortic Calcium, Coronary Artery Calcium, and Cardiovascular Morbidity and Mortality in the Multi-Ethnic Study of Atherosclerosis.
- Age at menopause and incident Heart failure: the Multi-Ethnic Study of Atherosclerosis.
- Association of Renin and Aldosterone With Ethnicity and Blood Pressure: The Multi-Ethnic Study of Atherosclerosis.
- A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.
- Predictors of cardiovascular risk in women.
- APOM and high-density lipoprotein are associated with lung function and percent emphysema.
- Reference ranges of PR duration and P-wave indices in individuals free of cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA).
- Fine particulate air pollution and the progression of Carotid intima-medial thickness: a prospective cohort study from the multi-ethnic study of atherosclerosis and ai...
- Genetic ancestry and the relationship of cigarette smoking to lung function and per cent emphysema in four race/ethnic groups: a cross-sectional study.
- Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.
- Sex differences in subclinical atherosclerosis by race/ethnicity in the multi-ethnic study of atherosclerosis.
- Treatment of Heart failure in African Americans--a call to action.
- Activated TLR signaling in atherosclerosis among women with lower Framingham risk score: the multi-ethnic study of atherosclerosis.
- Cardiovascular imaging for assessing cardiovascular risk in asymptomatic men versus women: the multi-ethnic study of atherosclerosis (MESA).
- Percent emphysema, airflow obstruction, and impaired left ventricular filling.
- Pitavastatin: the newest HMG-CoA reductase inhibitor.
- Do socioeconomic gradients in subclinical atherosclerosis vary according to acculturation level? Analyses of Mexican-Americans in the multi-ethnic study of atheroscler...
- The JUPITER trial: How will it change clinical practice?
- Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
- Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atheroscler...
- The impact of obesity on cardiovascular Disease risk factors and subclinical vascular Disease: the Multi-Ethnic Study of Atherosclerosis.
- What is the evidence in favor of low-dose statin therapy in 2008?
- Cardiovascular risk reduction among African Americans: a call to action.
- New insights into understanding cardiometabolic risk. Introduction.
- Pathogenesis of CHD: the role of elevated triglycerides.
- HDL function as a target of lipid-modifying therapy.
- Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
- Air pollution and heart Disease.
- Lowering levels of lipids and homocysteine.
- Treating to low-density lipoprotein goal: a tool for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis or similar risk.
- High-density lipoprotein function recent advances.
- Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting.
- Novel serum markers for risk prediction in Acute coronary syndromes.
- The past, present, and future of statin therapy.
- Anti-inflammatory properties of HDL.
- High-density lipoprotein cholesterol as a therapeutic target to reduce cardiovascular events.
- Pathobiology of atherosclerosis: are there racial and ethnic differences?
- The relationship between inflammation and atherosclerotic events.
- Cardiovascular Disease in African Americans. Introduction.
- Coronary heart disease care in older women: optimizing diagnostic and therapeutic decisions.
- Cardiovascular Disease in African Americans. Closing the knowledge, treatment, and outcome gap.
- Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance.
- Plasma lipoprotein concentrations in ethnic populations.
- Effective strategies for long-term statin use.
- Lessons learned from recent lipid-lowering trials: why physicians should change clinical practice.
- Lipid abnormalities in insulin resistant states.
- hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
- Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory.
- The metabolic Syndrome: recognition and management.
- Association of long-term air pollution with ventricular conduction and repolarization abnormalities.
- Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia.
- Intensive glycemic control and cardiovascular Disease observations from the ACCORD study: now what can a clinician possibly think?
- Bone morphogenetic protein expression in human atherosclerotic lesions.
- Atherosclerotic calcification: relation to developmental osteogenesis.
- TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify.
- For the patient. What is the Metabolic Syndrome and why is it important?
- Is neighborhood racial/ethnic composition associated with depressive symptoms? The multi-ethnic study of atherosclerosis.
- Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial Disease: insights from the reduction of at...
- Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.
- Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program.
- Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of Coronary heart disease from the multi-ethnic study of atherosclerosis.
- Association of salivary cortisol circadian pattern with cynical hostility: multi-ethnic study of atherosclerosis.
- Socioeconomic and race/ethnic differences in daily salivary cortisol profiles: the multi-ethnic study of atherosclerosis.
- Active serum vitamin D levels are inversely correlated with Coronary calcification.
- Geographic variation in Hypertension prevalence among blacks and whites: the multi-ethnic study of atherosclerosis.
- Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of Coronary calcium mass measured by electron-beam computed tomography.
- In-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes: the University of California-Los Angeles, Cardiovascula...
- Managing cardiometabolic risk: an evolving approach to patient care.
- An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
- Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
- Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic Syndrome and type 2 diabetes mellitus.
- Coronary calcium as a predictor of Coronary events in four racial or ethnic groups.
- Surgical risk in patients with metabolic Syndrome: focus on lipids and hypertension.
- Therapeutic lifestyle changes for Hypertension and cardiovascular risk reduction.
- Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.
- Quality indicators for the care of ischemic heart Disease in vulnerable elders.
- Guidelines for prevention of CVD in women.
- Multilineage potential of cells from the Artery wall.
- Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with Hypertension: results of the Extended-Release Ca...
- Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals.
- The atherosclerosis-calcification link?
- Mechanism of calcification in atherosclerosis.
- Pathophysiology of Coronary calcification.
- Hospital discharge treatments after an Acute event: evidence for a systems approach to prevention.
- The Metabolic Syndrome in African Americans: a review.
Schools
Harvard Medical School
University Of California Los Angeles
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- Arrhythmias (incl. Atrial Fibrillation)
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Assurant Health
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Humana
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- National Elevator
- UniCare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
Awards
- CMS Meaningful Use Stage 1 Certification
- Whos Who in Medicine and Healthcare
- Fellow (FACC)
- Super Doctor
Education
-
UCLA Medical Center -
Harvard Medical School
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1184646358 | |
| NPPES Provider LastName | WATSON | |
| NPPES Provider FirstName | KAROL | |
| NPPES Provider ZIPCode | 900953075 | |
| NPPES Provider State | CA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 676.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184646358 |
| Last Name Of The Provider | WATSON |
| First Name Of The Provider | KAROL |
| View All |
Similar Doctors
|
|
Dr. Tim S. Provias, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Houman Khakpour, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay N. Schapira, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gopal Govindarajan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel Cruz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shelley M. Shapiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Hyman, MD |
|
|
Dr. Linda X. Fong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herman H. Ricketts, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ray Zadegan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronen Goldkorn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne M. Ichiuji, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan S. Gordin, MD |
|
|
Dr. Tri M. Trinh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Mohinder S. Sohal, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Florian Rader, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miguel A. Salazar Jr., MD
This Doctor is OpenDoctor Recommended.
|